Salivary Gland Cancer

Salivary gland cancer is a rare disease in which malignant (cancer) cells form in the salivary gland tissue. There are three pairs of main salivary glands, which are parotid gland, sublingual gland, and submandibular gland. As a pioneer in the head and neck cancer field, Alfa Cytology provides a complete solution for salivary gland cancer.

Introduction to Salivary Gland Cancer

Salivary gland cancer is rare, accounting for only 3-5% of all head and neck cancers. The annual incidence rate varies by geographical region, with an estimated 2-4 cases per 100,000 people in the United States. Although the etiology of most salivary gland cancers is not yet clear, risk factors include the following.

Older

Perform radiation therapy on the head and neck

Exposure to certain substances in the workplace

A brief introduction diagram for salivary gland cancer. Fig.1 Schematic representation of salivary gland cancer features and prevalence in the major glands. (Bocchetti, M., et al., 2022)

Targets of Salivary Gland Cancer Therapy Development

For certain types of already spread salivary adenocarcinoma, molecular testing can be conducted to identify changes in certain proteins or genes to help select targeted drugs or immunotherapy drugs.

Androgen Receptor
(AR)

Approximately 25-30% of salivary gland cancers exhibit AR abnormalities. Anti-androgen therapies such as bicalutamide or enzalutamide may be effective.

Vascular Endothelial Growth Factor
(VEGF)

Drugs that inhibit VEGF signaling, such as tyrosine kinase inhibitors (TKIs) such as bevacizumab or sorafenib, have shown therapeutic potential in certain cases of salivary adenocarcinoma.

Fibroblast Growth Factor Receptor
(FGFR)

FGFR changes, including gene fusion or mutation, have been found in salivary adenocarcinoma. FGFR inhibitors, such as erdafitinib or pemigatinib, are being studied in clinical trials.

Therapy for Salivary Gland Cancer

The common therapies for salivary gland cancer include surgery, radiation therapy, and chemotherapy. In addition, there are also some new therapies under development.

PARP inhibitors: Poly-ADP ribose polymerase (PARP) inhibitors are being studied for their effects on salivary gland cancer, particularly in homologous recombination deficient (HRD) tumors. For example, the efficacy of Olaparib or Nilapani in treating HRD-positive salivary gland cancer.
Immunotherapy: Especially immune checkpoint inhibitors, have shown hope in treating certain salivary gland cancers. Checkpoint inhibitors, such as pembrolizumab or nivolumab, target proteins such as PD-1 or PD-L1 to enhance immune responses against cancer cells.

Our Services

Alfa Cytology is devoted to developing more effective and personalized therapy for salivary gland cancer. We provide one-stop solutions for salivary gland cancer, including but not limited to the following.

Cancer Diagnostic Development

Cancer Modeling Services

Preclinical Research Services

Salivary Gland Cancer Modeling Platform

The salivary gland cancer is a key tool in uncovering the complexities of this cancer. Alfa Cytology offers a range of models tailored to simulate the development and progression of salivary gland cancer cancer.

3D Tumor Modeling

Xenograft Model

Immuno-Oncology Tumor Models

Alfa Cytology also offers a range of animal model options specifically designed for laryngeal cancer, the species include mice, rats, zebrafish, chicks, dogs, non-human primates, and others. These models are crucial in understanding disease mechanisms, evaluating therapy outcomes, and developing new therapy strategies.

Alfa Cytology is committed to the research and study of cancer, from therapeutic antibody development services, cancer vaccine development services, to cancer modeling services, providing one-stop solutions. Our cancer experts have many years of experience in the development of the latest therapies for salivary gland cancer. If you are interested in our service, please contact us for more details.

Reference

Bocchetti, M., et al.; (2022) MicroRNAs' Crucial Role in Salivary Gland Cancers' Onset and Prognosis. Cancers, 14, 5304. https://doi.org/10.3390/cancers14215304.

For research use only.